OTC: NURPF - Neuren Pharmaceuticals Limited

Yield per half year: -33.59%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Neuren Pharmaceuticals Limited

Extended chart Simple chart
Financial Markets by TradingView

About Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares.

more details
Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.neurenpharma.com
Цена ао 6.86
Change price per day: 0% (6.86)
Change price per week: 0% (6.86)
Change price per month: -20.23% (8.6)
Change price per 3 month: -12.81% (7.868)
Change price per half year: -33.59% (10.33)
Change price per year: -49% (13.45)
Change price per 3 year: +114.82% (3.1934)
Change price per 5 year: +264.89% (1.88)
Change price per year to date: -9.38% (7.57)
All parameters

Underestimation

Title Value Grade
P/S 12.7 1
P/BV 14.35 1
P/E 18.75 7
EV/EBITDA 14.7 7
Total: 5.63

Efficiency

Title Value Grade
ROA, % 63.35 10
ROE, % 76.55 10
Total: 8.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 46756.97 10
Yield Ebitda, % -1821.79 0
Yield EPS, % -2025.02 0
Total: 2
More

Institutions Volume Share, %
Vanguard International Stock Index-Total Intl Stock Indx 1480133 1.16
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 877162 0.69
iShares Core MSCI EAFE ETF 652944 0.51
iShares MSCI EAFE Small Cap ETF 436465 0.34
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 403572 0.32
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 215442 0.17
iShares Core MSCI Total International Stock ETF 140892 0.11
Vanguard International Stock Index-Pacific Stock Index 128668 0.1
College Retirement Equities Fund-Stock Account 85378 0.07
SEI Institutional International Tr-International Equity 71485 0.06



Head Job title Payment Year of birth
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director 714.28k
Ms. Lauren Frazer C.A. CFO & Company Secretary N/A
Mr. Lawrence Glass BA (Biology) Chief Science Officer N/A
Mr. Gerry Zhao Vice President of Corporate Development N/A
Dr. Liza A. Squires M.D. Chief Medical Officer N/A

Address: Australia, Camberwell, 697 Burke Road - open in Google maps, open in Yandex maps
Website: https://www.neurenpharma.com